Pharmacodynamics in cancer therapy

Area of Science:

• Pharmacodynamics and pharmacokinetics in oncology
• Analytical and computational technology in drug development

Background:

• Therapeutic drug monitoring (TDM) is crucial for optimizing cancer treatment efficacy and safety.
• Currently, TDM is standard only for guiding leucovorin dosing in high-dose methotrexate therapy.
• Limited application of TDM in oncology hinders precise anticancer agent dosing.

Purpose of the Study:

• To review the recent advancements in analytical and computational technology for anticancer pharmacodynamics.
• To explore the emerging use of therapeutic drug monitoring for titrating antineoplastic agent doses.
• To discuss ongoing and future studies on optimizing drug dosing strategies in cancer therapy.

Main Methods:

• Review of recent studies utilizing real-time analysis of plasma drug or tissue concentrations.
• Analysis of completed and ongoing trials involving specific antineoplastic agents.
• Discussion of future research directions in pharmacodynamic modeling and drug monitoring.

Main Results:

• Significant progress in understanding anticancer pharmacodynamics and the link between drug levels and clinical outcomes.
• Emerging use of TDM to precisely titrate doses of agents like hexamethylene bisacetamide, etoposide, teniposide, fluorouracil (FUra), and cytarabine (ara-C).
• Empirical use of methotrexate plasma levels for leucovorin dosing remains a current standard.

Conclusions:

• Technological advancements are enhancing the precision of anticancer drug dosing.
• Expanding TDM applications beyond methotrexate holds promise for improved cancer treatment outcomes.
• Future research will focus on optimizing sampling, intermediate endpoints, combination therapies, and advanced pharmacodynamic models.